Long-acting Naltrexone for Pre-release Prisoners

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-01

Study Completion Date

2026-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This proposed five-year study will focus on whether the addition of providing XR-NTX treatment at a patients' place of residence will increase adherence and thus efficacy of the medication.Following initial screening, informed consent, and medical examination, pre-release prisoners at each facility will be block randomized (N=240) within gender to either: Condition 1. XR-NTX-OTx (n=120): One injection of XR-NTX in prison, followed by six monthly injections post-release in the community at an opioid treatment program; or Condition 2. XR-NTX+MMTx (n=120): One injection of XR-NTX in prison, followed by six monthly injections post-release in the community at the patient's place of residence.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail

NCT04408313

Opioid-use Disorder

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail

NCT01180647

Opiate Dependence

COMPLETED PHASE3

Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations

NCT01246401

HIV AIDS Opioid Dependence +1 more

COMPLETED PHASE1/PHASE2

Depot Naltrexone Treatment of Opioid Dependent Parolees

NCT00756990

Opioid Dependence

COMPLETED NA

Naltrexone Implants vs. MMT Among Inmates in the Norwegian Correctional Services

NCT00204243

Opiate Addiction

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Disorders involving opioid use are a severe problem among jail and prison inmates. Inmates in the US, Canada, Australia, and many European and Asian nations have disproportionately higher rates of opioid use disorders than their general populations. Scarce resources are provided for corrections-based substance use treatment in many nations, and many inmates with OUDs remain untreated. The use of long-acting, injectable naltrexone (XR-NTX) may be a promising form of treatment for pre-release prisoners. Naltrexone blocks the intoxicating and reinforcing effects of opioids, but has no opioid-like effects. This proposed five-year study will focus on whether the addition of providing XR-NTX treatment at a patients' place of residence will increase adherence and thus efficacy of the medication. Project implementation will occur at five pre-release prisons under the jurisdiction of the Maryland Department of Public Safety and Correctional Services (MDPSCS): 1) Metropolitan Transition Center (MTC) for men; 2) Baltimore Pre-Release Unit (BPRU) for men; 3) Jessup Pre-Release Unit (JPRU) for men; 4) Baltimore City Correctional Center (BCCC) and 5) Maryland Correctional Institution (MCI) for Women. Following initial screening, informed consent, and medical examination, pre-release prisoners at each facility will be block randomized (N=240) within gender to either: Condition 1. XR-NTX-OTx (n=120): One injection of XR-NTX in prison, followed by six monthly injections post-release in the community at an opioid treatment program; or Condition 2. XR-NTX+MMTx (n=120): One injection of XR-NTX in prison, followed by six monthly injections post-release in the community at the patient's place of residence. All participants will be confirmed opiate-free by urine test and negative naloxone and oral naltrexone tests, and evaluated monthly for seven months and 12 months after release from prison. The proposed study has two specific aims: Aim1. To compare the two study conditions in terms of: a) XR-NTX treatment adherence; b) opioid use; c) criminal activity; d) re-arrest; e) re-incarceration; and f) HIV risk-behaviors (i. needle use; ii. risky sexual behaviors). Aim 2. To determine if the number of months of post-release XR-NTX treatment is related to outcome (a-f above), and if so, is there a point at which XR-NTX v. Non-XR-NTX equilibrates? This would help determine the number of injections, important because of XR-NTX cost. Many individuals in the criminal justice system drop out of treatment and therefore increasing ways to improve adherence by attempting to: 1) expand capacity; and 2) implement access by providing treatment at their place of residence may positively impact outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opiate Addiction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vivitrol at place of residence

One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at the participants's place of residence utilizing mobile medical treatment

Group Type EXPERIMENTAL

XR-NTX

Intervention Type DRUG

Vivitrol

place of residence

Intervention Type OTHER

One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence

Vivitrol at opioid treatment program

One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at a community opioid treatment program.

Group Type ACTIVE_COMPARATOR

XR-NTX

Intervention Type DRUG

Vivitrol

opioid treatment program

Intervention Type OTHER

One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

XR-NTX

Vivitrol

Intervention Type DRUG

place of residence

One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence

Intervention Type OTHER

opioid treatment program

One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

long-acting naltrexone residence OTP

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult male or female inmate at MTC, BPRU, JPRU, BCCC, or MCIW and be eligible for release within 30 days
* History of opiate disorder \[meeting DSM-V criteria of dependence at the time of incarceration\]
* Suitability for XR-NTX treatment as determined by medical evaluation
* Currently opioid-free by history, with negative urine for all opioids and no signs of opiate withdrawal
* Willingness to enroll in XR-NTX treatment in prison \[not currently in or planning to pursue agonist (methadone, buprenorphine) treatment at release\]
* Planning to live in Baltimore City or County.
* Inmates not meeting the opioid-dependence criterion will be eligible if they were treated in an opioid agonist treatment program during the year before incarceration

Exclusion Criteria

* Liver function test levels greater than three times normal
* Active medical illness that may make participation hazardous (e.g., unstable diabetes, heart disease). Adequately treated medical conditions are acceptable
* Untreated psychiatric disorder that may make participation hazardous (e.g., untreated psychosis, bipolar disorder with mania). Adequately treated psychiatric disorders and appropriate psychotropic medications will be allowed
* History of allergic reaction to XR-NTX
* Current chronic pain diagnosis for which opioids are prescribed
* Creatinine above normal limits
* Pregnancy (for women)
* Breast-feeding (for women)
* Suicidal ideation (within the past 6-months)
* Body Mass Index (BMI) \> 40
* Unadjudicated charges that may result in transfer to another facility and/or additional prison time.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes